FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Aarti Drugs's FCF Yield % or its related term are showing as below:
NSE:AARTIDRUGS'
s FCF Yield % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.32
Current: 2.27
During the past 13 years, the highest FCF Yield % of Aarti Drugs was 2.32%. The lowest was 0.00%. And the median was 0.00%.
NSE:AARTIDRUGS's FCF Yield % is ranked better than 61.07% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.67
vs NSE:AARTIDRUGS: 2.27
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Aarti Drugs FCF Yield % Related Terms
Aarti Drugs FCF Yield % Historical Data
* Premium members only.
The historical data trend for Aarti Drugs's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:AARTIDRUGS vs ZTS, UTHR: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Drugs FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Aarti Drugs's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Drugs (NSE:AARTIDRUGS) has a FCF Yield % of 2.27 as of Jul. 08, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Aarti Drugs and its competitors. According to the industry distribution chart, Aarti Drugs ranks #392 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 38.9%.
Is Aarti Drugs' FCF Yield % too high?
Aarti Drugs' current FCF Yield % is 2.27. The Drug Manufacturers industry median FCF Yield % is 0.67. Aarti Drugs' value of 2.27 is 238.8% above this industry median. Based on the distribution chart, Aarti Drugs ranks #392 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aarti Drugs has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Drugs' FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aarti Drugs ranks #392 out of 1007 companies for FCF Yield %. This puts Aarti Drugs in the upper half of its industry. The industry median FCF Yield % is 0.67. Aarti Drugs' value of 2.27 is 238.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Drugs's current FCF Yield % of 2.27 is 238.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Aarti Drugs and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Drugs's current FCF Yield % is 2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Drugs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Drugs (NSE:AARTIDRUGS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹497.92, compared to a current price of ₹388.95 — trading 21.9% below its estimated fair value. The current FCF Yield % is 2.27 and 238.8% above the Drug Manufacturers industry median of 0.67. Aarti Drugs' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Aarti Drugs (NSE:AARTIDRUGS), the current FCF Yield % is 2.27 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued.
The current stock price of ₹388.95 is trading 21.9% below its estimated GF Value™ of ₹497.92.
GuruFocus considers Aarti Drugs to be Modestly Undervalued.
Key valuation signals for NSE:AARTIDRUGS:
FCF Yield %: 2.27
GF Value™: ₹497.92 vs. price of ₹388.95 (21.9% below fair value)
Industry Position: 238.8% above the Drug Manufacturers median (#392 of 1007)
No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
73GF Score
Get the complete analysis for NSE:AARTIDRUGS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIDRUGS has been successfully added to your 
